HOME ¥µ¥¤¥È¥Þ¥Ã¥× ¥×¥é¥¤¥Ð¥·¡¼¥Ý¥ê¥·¡¼ »ö¶È³µÍ× ¤ªÌä¹ç¤»
HOME¡¡> ºÇ¿·°åÎÅ¥»¥ß¥Ê¡¼³«ºÅ¥¹¥±¥¸¥å¡¼¥ë¡¡> ¥»¥ß¥Ê¡¼¾ÜºÙ¡Ê¼ÂÃϰå²È¤Î¤¿¤á¤Î¡¡¿´ÉÔÁ´¡¡ÌôʪÎÅË¡¤Î¿·Ä¬Î®¡Ë

¼ÂÃϰå²È¤Î¤¿¤á¤Î¡¡¿´ÉÔÁ´¡¡ÌôʪÎÅË¡¤Î¿·Ä¬Î®

ºÇ¿·°åÎÅ¥»¥ß¥Ê¡¼¾ÜºÙ¡ÚºÇ¿·°åÎŵ»½Ñ¥»¥ß¥Ê¡¼¡Ö¥¹¥­¥ë¥¢¥Ã¥×¡×¡Û
¥»¥ß¥Ê¡¼¾ÜºÙ
¡¡°åΟ½¾ì¤Ç¤Î¥È¥Ô¥Ã¥¯¥¹¤äÎΰèÊÌ¡¦¼À´µÊ̤ËÃåÌܤ·¤¿¥»¥ß¥Ê¡¼¤ò³«ºÅ¤¤¤¿¤·¤Þ¤¹¡£
¥»¥ß¥Ê¡¼¥¹¥±¥¸¥å¡¼¥ë¥À¥¦¥ó¥í¡¼¥É¡ÊPDF¥Õ¥¡¥¤¥ë¡Ë
LiveÃæ·Ñ¹Ô¤¤¤Þ¤¹
¢£º¸¤Î¥Þ¡¼¥¯¤¬ÉÕ¤¤¤Æ¤¤¤ë¥»¥ß¥Ê¡¼¤Ï¡¢¥¤¥ó¥¿¡¼¥Í¥Ã¥È¤ÇLiveÃæ·Ñ¤ò¹Ô¤¤¤Þ¤¹¡£
¢¨¥»¥ß¥Ê¡¼³«ºÅÆü¤ËÅÔ¹ç¤ÇÍè¾ì¤Ç¤­¤Ê¤¤Êý¤äÃÏÊý¤ÎÊý¡¹¤ÎÍøÊØÀ­¸þ¾å¤Î¤¿¤á¤Ë¡¢¥¤¥ó¥¿¡¼¥Í¥Ã¥È¤òÄ̤¸¤Æ
¡¡ ¥Í¥Ã¥ÈÃæ·Ñ¤ò¹Ô¤¤¤Þ¤¹¡£¥Í¥Ã¥È¼õ¹Ö¤Î¾ÜºÙ¤Ï¤³¤Á¤é¤ò¤´Í÷¤¯¤À¤µ¤¤¡£
¥»¥ß¥Ê¡¼ÆüÄø¤ËÌá¤ë
LiveÃæ·Ñ¹Ô¤¤¤Þ¤¹
¼ÂÃϰå²È¤Î¤¿¤á¤Î¡¡¿´ÉÔÁ´¡¡ÌôʪÎÅË¡¤Î¿·Ä¬Î®
¡ÝWHF(Worsening Herat Failure)¤ËÂФ¹¤ëÀïά¤ò¤É¤¦¹½ÃÛ¤¹¤ë¤«¡£¡Ý
¡Ú¥»¥ß¥Ê¡¼³µÍסÛ
¡¡ÃIJô¤ÎÀ¤Â夬75ºÐ°Ê¾å¤Î¸å´ü¹âÎð¼Ô¤Ë¤Ê¤ë2025ǯ¤òÌÜÁ°¤Ë¿´ÉÔÁ´´µ¼Ô¤ÎÀäÂпô¤ÏÁý²Ã¤Î°ìÅÓ¤ò¤¿¤É¤Ã¤Æ¤ª¤ê¡¢À¤³¦Åª¤Ë¤âÀè¿Ê¹ñ¤Ë¤ª¤±¤ë¿´ÉÔÁ´¿ÇÎŤνÅÍ×À­¤ÏÁýÂ礷¤Æ¤¤¤ë¡£¤³¤Î¤è¤¦¤Ê´Ä¶­¤ÎÃæ2014ǯ¤ÎARNI¡ÊAngiotensin Receptor-Neprilysin Inhibitor¡Ë¤Îº¸¼¼¶î½ÐΨ¤ÎÄã²¼¤·¤¿¿´ÉÔÁ´¡ÊHFrEF¡Ë¤ËÂФ¹¤ëRCT¤Ç¤¢¤ëPARADIGM»î¸³¤ÎÀ®¸ù¤òÈéÀÚ¤ê¤Ë¿¤¯¤Î¿´ÉÔÁ´¼£ÎÅÌô¤Î¥¨¥Ó¥Ç¥ó¥¹¤Îȯɽ¤¬Â³¤¤¤Æ¤¤¤ë¡£ARNI¡¢SGLT2Á˳²Ìô¡¢MRA¤½¤·¤ÆIf ¼õÍÆÂÎÁ˳²ÌôIvabradine¡¢²ÄÍÏÀ­Ž¸ŽÞޱޯŽÙ»À¥·¥¯¥é¡¼¥¼¡ÊsGC¡ËÁ˳²ÌôVericiguat¡¢ÁªÂòۥߥª¥·¥ó³èÀ­²½ÌôOmecamtiv¡¡mecarbil¤ÎRCT¤Î·ë²Ì¤òÀ°Íý¤·HFrEF¤ÎÌôʪ¼£ÎŤε­ºÜ¤¬ÆüÊÆ²¤¤Î¥¬¥¤¥É¥é¥¤¥ó¤Ç¤É¤¦ÊѲ½¤·¤¿¤«¤ò¾Ò²ð¤·¤¿¤¤¡£°ìÊý¤Çº¸¼¼¶î½ÐΨ¤ÎÊݤ¿¤ì¤¿¿´ÉÔÁ´¡ÊHFpEF¡Ë¤ËÂФ¹¤ë¼£ÎÅÀïά¤Ï°ì¶ÚÆì¤Ç¤Ï¤¤¤«¤Ê¤¤¡£HFpEF¤ËÂФ¹¤ëÌôʪÎÅË¡¤Î¥¨¥Ó¥Ç¥ó¥¹¤Ï¤É¤¦¤Ê¤Ã¤Æ¤¤¤ë¤Î¤«¤òHFpEF¤ÎÉÂÂ֤οÍÍÀ­¤ä¸¶¼À´µ¤ÎÁê°ã¤Ê¤É¤â´Þ¤á¤Æ²òÀ⤷¤½¤ÎÍý²ò¤Ë¤Ä¤Ê¤²¤¿¤¤¡£¼ÂÃϰå²Ê¤ÎÀèÀ¸Êý¤Î¿´ÉÔÁ´¼£ÎŤòupdate¤¹¤ë¤­¤Ã¤«¤±¤Ë¤·¤Æ¤¤¤¿¤À¤±¤ì¤Ð¹¬¿Ó¤Ç¤¢¤ë¡£
¡¡³§¤µ¤Þ¡¢Ê³¤Ã¤Æ¤´»²²Ã¤¯¤À¤µ¤¤¡£
10:00¡Á12:00¡§HFrEF¤Î¼£ÎÅÀïά:Fantastic4¡ÜIvabradine¡¢Vericiguat¤ò¤É¤¦»È¤Ã¤Æ¤¤¤¯¤«¡£
­¡ÆüËܤο´ÉÔÁ´¤Î±Ö³Ø
­¢HFrEF¤ËÂФ¹¤ëÌôʪ¤ÎÊÑÁ«¤È2010ǯ°Ê¹ß¤ÎRCT¤Î¾Ò²ð
­£º¸¼¼¥ê¥â¥Ç¥ê¥ó¥°¤Ë±Æ¶Á¤òÍ¿¤¨¤ë°ø»Ò
­¤ÆüÊÆ²¤¤Î¥¬¥¤¥É¥é¥¤¥ó¡§É¸½à¼£ÎŤξҲð
­¥¼ÂÎ×¾²¤Ë¤ª¤±¤ëWHFͽËɤÎÀïά¡§¥±¡¼¥¹¥¹¥¿¥Ç¥¤¡¼

12:00~12:30¡§µÙ·Æ

12:30¡Á14:30¡§HFpEF¤È¤¤¤¦ÉÂÂÖ¤ò¤É¤¦Íý²ò¤¹¤ë¤«¡©HFmrEF¡¢HFpEF¤ËÂФ¹¤ë¼£ÎÅÀïά¤ò¤É¤¦ÁȤßΩ¤Æ¤ë¤«¡¢
­¡HFpEF¤È¤Ï²¿¤«¡©Â¿ºÌ¤ÊÉÂÂÖ¤ÎÍý²ò¤È´ÕÊÌ¿ÇÃÇ
­¢¿´ÉÔÁ´¤òº¸¼¼¶î½ÐΨ¤Çʬ¤±¤ë¤³¤È¤ÎÌäÂêÅÀ¤È¤Ï¡©
­£HFpEF¤ÎÌôʪÎÅË¡¤Î¥¨¥Ó¥Ç¥ó¥¹
­¤ÈóÌôʪÎÅË¡¤ÈÊñ³çŪ¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó
­¥¼ÂÎ×¾²¤Ë¤ª¤±¤ëWHFͽËɤÎÀïά¡§¥±¡¼¥¹¥¹¥¿¥Ç¥¤¡¼

¹¾ÇȸÍÈþ½ïÀèÀ¸
¢£¹Ö»Õ
¹¾ÇȸÍÈþ½ï ÀèÀ¸
¡Ê¾¼ÏÂÂç³Ø°å³ØÉôÉí°ƣ¤¬µÖɱ¡½Û´Ä´ïÆâ²Ê¡¡¶µ¼ø¡Ë
¡ãάÎò¡ä
83ǯ3·î¡¡Ì¾¸Å²°Âç³Ø°å³ØÉô°å³Ø²Ê´¶È
85ǯ9·î¡¡¼Ò²ñÊݸ±Ãæµþɱ¡Æâ²ÊÎ×¾²¸¦½¤°å¥×¥í¥°¥é¥à½ªÎ»
85ǯ10·î¡¡¾¼ÏÂÂç³ØÆ£¤¬µÖɱ¡½Û´Ä´ïÆâ²ÊÁ°´ü½õ¼ê
91ǯ4·î¡¡¾¼ÏÂÂç³ØÆ£¤¬µÖɱ¡½Û´Ä´ïÆâ²Ê½õ¼ê
92ǯ4·î¡¡¾¼ÏÂÂç³ØÆ£¤¬µÖɱ¡Î×¾²ÉÂÍý²Ê½õ¼ê
01ǯ12·î¡¡Atlanta Cardiovascular Research Institute Research Fellow
03ǯ4·î¡¡¾¼ÏÂÂç³ØÆ£¤¬µÖɱ¡Î×¾²ÉÂÍý½õ¼ê
05ǯ4·î¡¡¾¼ÏÂÂç³ØÆ£¤¬µÖɱ¡½Û´Ä´ïÆâ²Ê¹Ö»Õ
14ǯ3·î¡¡¾¼ÏÂÂç³ØÆ£¤¬µÖɱ¡½Û´Ä´ïÆâ²Ê½Ú¶µ¼ø
17ǯ8·î¡Á¸½ºß¡¡
¡¡¡¡¡¡¡¡ ¾¼ÏÂÂç³ØÆ£¤¬µÖɱ¡½Û´Ä´ïÆâ²Ê¶µ¼ø

¡ã»ñ³Ê¡ä
ÆüËÜÆâ²Ê³Ø²ñÀìÌç°å¡¢ÆüËÜ½Û´Ä´ï³Ø²ñ½Û´Ä´ïÀìÌç°å¡¢ÆüËÜͲ»ÇȳزñÀìÌç°å¡¢»ØÆ³°å
ÆüËÜ¿´¥¨¥³¡¼¿Þ³Ø²ñ¿´¥¨¥³¡¼ÀìÌç°å
ÆüËÜ¿´Â¡É³زñɾµÄ°÷¡¢ÆüËÜ¿´ÉÔÁ´³Ø²ñɾµÄ°÷¡¢ÆüËÜ½Û´Ä´ï³Ø²ñ´ØÅì¹Ã¿®±ÛÃÏÊý²ñɾµÄ°÷

FACP: Fellow of American College of Physicians¡¡¡ÊÊÆ¹ñÆâ²Ê³Ø²ñ¡Ë
FJCS: Fellow of Japanese College of Cardiology ¡ÊÆüËÜ¿´Â¡É³زñ¡Ë¡¡
FACC: Fellow of Japanese Circulation Society¡ÊÆüËÜ½Û´Ä´ï³Ø²ñ¡Ë

FAX¤Ç¿½¤·¹þ¤ß¡ÊPDF¥Õ¥¡¥¤¥ë¥À¥¦¥ó¥í¡¼¥É¡Ë²ñ¾ì¼õ¹Ö¿½¤·¹þ¤ß¥Í¥Ã¥È¼õ¹Ö¿½¤·¹þ¤ß
¥»¥ß¥Ê¡¼Í×¹Ë
¡¡¥»¥ß¥Ê¡¼No
687
¡¡³«ºÅÆü
2022ǯ7·î10Æü¡ÊÆü¡Ë 10:00¡Á14:30 ¢¨³«¾ì 9:30
¡¡¥»¥ß¥Ê¡¼²ñ¾ì
¥¢¥Ã¥È¥Ó¥¸¥Í¥¹¥»¥ó¥¿¡¼ Åìµþ±ØÈ¬½Å½§Ä̤ê
¡ÊÅìµþÅÔÃæ±û¶èȬÃúËÙ1-9-8 Ȭ½Å½§Ḁ̈ϥ¿¥Ó¥ë6F¡Ë
¡¡¹Ö»Õ
¢£¹¾ÇȸÍÈþ½ï ÀèÀ¸¡Ê¾¼ÏÂÂç³Ø°å³ØÉôÉí°ƣ¤¬µÖɱ¡½Û´Ä´ïÆâ²Ê¡¡¶µ¼ø¡Ë
¡¡¼õ¹ÖÎÁ
¡Ú°å»Õ¡Û
¢£²ñ¾ì¼õ¹Ö¡§ 40,000 ±ß¡Ê¤ª°ì¿ÍÍÍ/Àǹþ¤ß¡Ë
¢£¥Í¥Ã¥È¼õ¹Ö¡§20000 ±ß¡Ê¥¹¥Ý¥Ã¥È¡Ë¡¢¢¨½é´üÅÐÏ¿ÎÁ¡§5,000 ±ß¡ÊºÇ½é¤Î1²ó¤Î¤ß¡Ë
¡¡Ê¬Ìî/ÂоÝ
¢£Ê¬Ìî¡§ ¿ÇÎÅ¡¦¿Ç»¡µ»½Ñ
¢£Âоݡ§ °å»Õ/´Ç¸î»Õ/ÌôºÞ»Õ
¥»¥ß¥Ê¡¼²ñ¾ì°ÆÆâ¿Þ
¢£¥¢¥Ã¥È¥Ó¥¸¥Í¥¹¥»¥ó¥¿¡¼ Åìµþ±ØÈ¬½Å½§Ä̤ê
¡ÊÅìµþÅÔÃæ±û¶èȬÃúËÙ1-9-8 Ȭ½Å½§Ḁ̈ϥ¿¥Ó¥ë6F¡Ë
¥»¥ß¥Ê¡¼²ñ¾ìÊѹ¹¤Î¤´°ÆÆâ
¤´Ãí°Õ!! 9·î28Æü¤Ë³«ºÅ¤µ¤ì¤ë¥»¥ß¥Ê¡¼¤«¤é¡¢²¼µ­¤Î²ñ¾ì¤Ç¤¢¤ê¤Þ¤¹¡Ö¥¹¥¿¥ó¥À¡¼¥É²ñµÄ¼¼ ÆüËܶ¶¼¼Ä®Å¹¡×¤ËÊѤï¤ê¤Þ¤¹¡£²ñ¾ì¼õ¹Ö¤ÎÊý¡¹¤Ë¤Ï¤´ÌÂÏǤò¤ª¤«¤±¤·¤Þ¤¹¤¬¡¢¤É¤¦¤¾¤´ÍƼϤ¯¤À¤µ¤¤¡£
¢£¿·²ñ¾ì
¥¹¥¿¥ó¥À¡¼¥É²ñµÄ¼¼ ÆüËܶ¶¼¼Ä®Å¹

¢©103-0023¡¡ÅìµþÅÔÃæ±û¶èÆüËܶ¶ËÜÄ®1-6-1 ´ÝÇð¥Ó¥ë3F
²ñ¾ì°ÆÆâ¿Þ
¡ãºÇ´ó¤ê±Ø¡ä
¢£JRÀþ ¡ÖÅìµþ±Ø¡×Ȭ½Å½§Ë̸ý¤è¤êÅÌÊâ15ʬ
¢£JRÀþ ¡Ö¿ÀÅıء×Åì¸ý¤è¤êÅÌÊâ13ʬ
¢£Åìµþ¥á¥È¥í¶äºÂÀþ/Ⱦ¢ÌçÀþ ¡Ö»°±ÛÁ°±Ø¡×A6½Ð¸ý¤è¤ê ÅÌÊâ5ʬ
¢£Åìµþ¥á¥È¥í¶äºÂÀþ/ÅÔ±ÄÀõÁðÀþ ¡ÖÆüËܶ¶±Ø¡×D2½Ð¸ý¤è¤ê ÅÌÊâ8ʬ
FAX¤Ç¿½¤·¹þ¤ß¡ÊPDF¥Õ¥¡¥¤¥ë¥À¥¦¥ó¥í¡¼¥É¡Ë²ñ¾ì¼õ¹Ö¿½¤·¹þ¤ß¥Í¥Ã¥È¼õ¹Ö¿½¤·¹þ¤ß
¢¥¥Ú¡¼¥¸¤ÎÀèÆ¬¤ËÌá¤ë
¥»¥ß¥Ê¡¼¾ðÊó
²ñ¼Ò°ÆÆâ¥À¥¦¥ó¥í¡¼¥É
̵ÎÁÂθ³¥»¥ß¥Ê¡¼¡Ú̵ÎÁư²èÇÛ¿®Ã桪¡Û
¥»¥ß¥Ê¡¼½ªÎ»Êó¹ð
¤ªÃΤ餻
»ö¶È³µÍס¡|¡¡¤ªÌ䤤¹ç¤ï¤»¡¡|¡¡¥µ¥¤¥È¥Þ¥Ã¥×¡¡|¡¡¥×¥é¥¤¥Ð¥·¡¼¥Ý¥ê¥·¡¼